• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Novavax Submits EUA for Protein-based COVID-19 Vax Booster

    BeiGene, Ontada Enter Strategic Oncology Alliance

    AskBio Appoints Clinical Ops Executives

    SpectrumX Partners With UK Contract Manufacturer

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    SpectrumX Partners With UK Contract Manufacturer

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Catalent to Acquire Metrics Contract Services for $475M
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    UPS to Acquire Healthcare Logistics Provider Bomi Group

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Novavax Submits EUA for Protein-based COVID-19 Vax Booster

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    West Pharmaceutical Makes Strategic Investment in Latch Medical

    “3 Key Trends” with James Park

    Captor Therapeutics Selects CDMO for Clinical Trial Materials
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Kyongbo Pharmaceutical

    CMC Pharmaceuticals

    Biosynth Carbosynth

    Societal CDMO

    IDT Biologika
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Kyongbo Pharmaceutical

    CMC Pharmaceuticals

    Biosynth Carbosynth

    Societal CDMO

    IDT Biologika
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    Pfizer, Inc.

    ...

    Pfizer, Inc.
    Related CONTENT
    • Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
    • COVID Booster Vaccines: What’s Next for FDA
    • Choosing and Managing a CDMO
    • Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines
    • FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY
    07.15.19
    Headquarters: New York, NY
    twitter.com@pfizer_news
    www.pfizer.com



    Headcount: 92,400
    Year Established: 1849
    Revenues:  $53,647  (+2%)
    Net Income:  $11,153  (-48%)
    R&D:  $8,006  (+4%)

    TOP SELLING DRUGS
    Drug Indication 2018 (+/-%)
    Prevnar 13 pneumoccal vaccine $5,802 4%
    Lyrica epilepsy, neuropathy $4,970 -2%
    Ibrance cancer $4,118 32%
    Enbrel rheumatoid arthritis $2,112 -14%
    Lipitor cholesterol $2,062 8%
    Xeljanz arthritis $1,774 32%
    Chantix smoking cessation $1,085 9%
    Sutent cancer $1,049 -3%
    Norvasc hypertention $1,024 11%
    Premarin menopause $832 -15%


    In 2018, Pfizer reported revenues of $53,647 billion, an increase of two percent, as several of its biggest-selling medicines and vaccines continued to grow, including Ibrance, Eliquis, Xeljanz and Prevnar 13. Pfizer also reported growth in emerging markets and in biosimilars, which helped to absorb $1.7 billion in lost revenue because of products that recently lost marketing exclusivity. Eight billion dollars was invested during the year in research and development (R&D).

    During the year, Pfizer unveiled plans to reorganize into three businesses, which became effective at the beginning of the company’s 2019 fiscal year, and are Pfizer Biopharmaceuticals Group, that now includes biosimilars and a new Hospital business unit for anti-infectives and sterile injectables; Upjohn, an off-patent branded and generic medicines business based in China that is bringing 20 of its most iconic brands to more than 100 markets around the world; and a Consumer Healthcare business aligned with the growing trend of consumers taking their health into their own hands.

    Also on the consumer side of the business, at the end of the year Pfizer and GlaxoSmithKline entered a joint venture to create a global consumer healthcare company. The deal calls for Pfizer contributing its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The 2017 global sales for the combined business were approximately $12.7 billion. The deal is expected to close in the second half of 2019.

    The joint venture will be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health and therapeutic oral health. It’s expected to be among the largest consumer healthcare players in key geographies, including the U.S., Europe, China, India and Australasia. The joint venture will operate globally under the GSK Consumer Healthcare name. Following the integration, GSK intends to separate the joint venture as an independent company.

    As we moved into 2019, it was announced that Dr. Albert Bourla, chief operating officer at the time, would be taking over the reins of the stripped down Pfizer organization as its new chief executive officer, succeeding Ian Read. Under Mr. Read, Pfizer received 30 FDA approvals and amassed a pipeline with the potential for approximately 25-30 approvals through 2022, of which as many as 15 have the potential to be blockbusters.

    Sterile manufacturing investment
    In terms of growth, Pfizer is investing $465 million to expand its U.S. manufacturing with technically advanced sterile injectable pharmaceutical production facilities in Portage, MI, which will create approximately 450 new jobs over the next several years. Known as Modular Aseptic Processing (MAP), the new 400,000 square foot production facility expands Pfizer’s presence in Portage, located in Kalamazoo County, where the company now employs more than 2,200 people at one of its largest plants.

    MAP will incorporate technically advanced aseptic manufacturing equipment, systems and design, including multiple, self-contained modular manufacturing lines. This allows the manufacturing line in each module to be entirely separate from all other manufacturing lines. Construction is expected to be completed in 2021. After the facility is validated by regulatory agencies, production should begin in 2024.

    The investment is part of Pfizer’s overall plan to invest approximately $5 billion in U.S.-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act. During the next six years, the company expects to invest approximately $1.1 billion in Kalamazoo County, which is in addition to the $1 billion it has invested in the site over the past decade.

    The Portage site is a primary global supplier of sterile injectable, liquids and semi-solid medicines, and active pharmaceutical ingredients (APIs), producing more than 150 products. Its biggest product is Solu-Medrol, a widely used injectable anti-inflammatory medicine.

    Cancer research collaborations
    Pfizer remained active during the year on the cancer research front. It inked a deal worth up to $520 million with Kineta Immuno-Oncology (KIO), to develop RIG-I agonist immunotherapies for the treatment of cancer.

    Leap Therapeutics entered into a collaboration with Pfizer and Merck KGaA to evaluate Leap’s GITR agonist, TRX518, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. Avelumab has received accelerated approval by the FDA for the treatment of patients with metastatic Merkel cell carcinoma (MCC) and previously treated patients with locally advanced or metastatic urothelial carcinoma (mUC), and is under further clinical evaluation across a range of tumor types under a global strategic alliance between Merck KGaA and Pfizer.

    Daiichi Sankyo also entered into a clinical trial collaboration agreement with Pfizer and Merck KGaA to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors. 

    A separate research collaboration to conduct preclinical studies evaluating [fam-] trastuzumab deruxtecan in combination with avelumab, the DDR inhibitor and other investigational compounds in Merck KGaA’s and Pfizer’s pipelines is also underway.

    Aside from cancer, during the year Pfizer also signed a $425 million flu vaccine deal with BioNTech AG, a biotech focused on precise immunotherapies for the treatment of cancer and infectious disease. The multi-year R&D collaboration’s goal is to develop mRNA-based vaccines for the prevention of influenza (flu). 
    Related Searches
    • china
    • glaxosmithkline
    • consumer healthcare
    • generic
    Suggested For You
    Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
    COVID Booster Vaccines: What’s Next for FDA COVID Booster Vaccines: What’s Next for FDA
    Choosing and Managing a CDMO Choosing and Managing a CDMO
    Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines
    FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY
    Pfizer to Acquire Trillium Therapeutics for $2.3B Pfizer to Acquire Trillium Therapeutics for $2.3B
    FDA Amends EUAs for COVID-19 Vaccines FDA Amends EUAs for COVID-19 Vaccines
    BioNTech’s 2Q Revenue Soars BioNTech’s 2Q Revenue Soars
    A Look Into COVID Vaccines, Development and Outsourcing A Look Into COVID Vaccines, Development and Outsourcing
    VideoBites: Pfizer CentreOne VideoBites: Pfizer CentreOne
    Pfizer Pfizer's 2Q Revenues Up 92%
    ImmunoGenesis Opens Research Lab, Adds Key Roles ImmunoGenesis Opens Research Lab, Adds Key Roles
    U.S. Govt. Buys Additional 200M Doses of Pfizer-BioNTech COVID Vax U.S. Govt. Buys Additional 200M Doses of Pfizer-BioNTech COVID Vax
    Pfizer, BioNTech Partner with Biovac for COVID-19 Vax in Africa Pfizer, BioNTech Partner with Biovac for COVID-19 Vax in Africa
    Biogen Biogen

    Related Breaking News

    • Breaking News | Promotions & Moves
      Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer

      Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer

      Schetter has a proven track record across the entire biopharmaceutical value chain.
      09.20.21

    • Biologics, Proteins, Vaccines
      COVID Booster Vaccines: What’s Next for FDA

      COVID Booster Vaccines: What’s Next for FDA

      FDA Atty comments on the ongoing vaccine rollout what we can expect for other COVID vaccines in development going forward.
      09.13.21

    • Choosing and Managing a CDMO

      Choosing and Managing a CDMO

      Speed up your time-to-market, keep development costs under control and smooth the FDA approval and commercial launch process.
      Dana Toops, President, Avema Pharma Solutions 09.09.21


    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
      Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines

      Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines

      The annual production is expected to exceed 100 million finished doses annually for Latin America.
      08.26.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News | Regulatory Affairs
      FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY

      FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY

      Grants first full approval for COVID vaccine.
      08.23.21

    Loading, Please Wait..
    Trending
    • Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    • Pfizer, Neurocrine Terminate Collaboration
    • Almac Invests $65M To Expand North American HQ
    • Catalent To Acquire Metrics Contract Services For $475M
    • Novavax Submits EUA For Protein-based COVID-19 Vax Booster
    Breaking News
    • Novavax Submits EUA for Protein-based COVID-19 Vax Booster
    • BeiGene, Ontada Enter Strategic Oncology Alliance
    • AskBio Appoints Clinical Ops Executives
    • GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    • SpectrumX Partners With UK Contract Manufacturer
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    What are you Reading this Week?
    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Spartech Promotes Three Staff Members
    Elisabeth Lackner Named Chief Scientific Officer at Element Materials Technology
    Natech Plastics Purchases Three New Injection Molding Machines
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Novavax Submits EUA for Protein-based COVID-19 Vax Booster
    BeiGene, Ontada Enter Strategic Oncology Alliance
    AskBio Appoints Clinical Ops Executives
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Maelys Rolls Out to Ulta Beauty
    The Body Shop Encourages Young People to Vote
    Weekly Recap: Howard Kaneff Dies, Keys Soulcare Adds SPF Skincare Offering & More
    Happi

    Latest Breaking News From Happi

    In-Cosmetics Asia Returns to Bangkok to Deliver Look at Market Trends and Ingredient Innovations
    Perfect Corp. AI Skin Analysis Beauty SaaS Brand Console Is HIPAA-Compliant
    Black-Owned Dinobi Detergent Uses Plant-Based Green Ingredients
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Printing Ink Primer, Zeller+Gmelin Lead This Week’s News Stories
    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Pro Label Inc. installs first Mark Andy DSiQ hybrid press
    Gallus launches Gallus One inkjet label press
    Esko, Constantia Flexibles announce acquisitions and more
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Daio Paper Acquires Pet Care Products Manufacturer
    Honest Reports Increased Revenue
    Weekly Recap: Essity Switches to Recyclable Packs for Feminine Pads, FTC Sues PPE Maker on False Origin Claims & More
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FundamentalVR Raises $20 Million in Series B Funding
    Bioventus Achieves Strong Growth in Q2 2022
    Bone Void Fillers Market Growing at 6%
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories
    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login